232 related articles for article (PubMed ID: 26527750)
1. Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer.
Montgomery B; Eisenberger MA; Rettig MB; Chu F; Pili R; Stephenson JJ; Vogelzang NJ; Koletsky AJ; Nordquist LT; Edenfield WJ; Mamlouk K; Ferrante KJ; Taplin ME
Clin Cancer Res; 2016 Mar; 22(6):1356-63. PubMed ID: 26527750
[TBL] [Abstract][Full Text] [Related]
2. Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer.
Taplin ME; Antonarakis ES; Ferrante KJ; Horgan K; Blumenstein B; Saad F; Luo J; de Bono JS
Eur Urol; 2019 Dec; 76(6):843-851. PubMed ID: 31542304
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Therapies After Galeterone in Patients With Castration-resistant Prostate Cancer.
McKay RR; Werner L; Fiorillo M; Roberts J; Heath EI; Bubley GJ; Montgomery RB; Taplin ME
Clin Genitourin Cancer; 2017 Aug; 15(4):463-471. PubMed ID: 27890446
[TBL] [Abstract][Full Text] [Related]
4. Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor.
Yu Z; Cai C; Gao S; Simon NI; Shen HC; Balk SP
Clin Cancer Res; 2014 Aug; 20(15):4075-85. PubMed ID: 24874833
[TBL] [Abstract][Full Text] [Related]
5. Galeterone for the treatment of advanced prostate cancer: the evidence to date.
Bastos DA; Antonarakis ES
Drug Des Devel Ther; 2016; 10():2289-97. PubMed ID: 27486306
[TBL] [Abstract][Full Text] [Related]
6. Galeterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts in vivo.
Kwegyir-Afful AK; Ramalingam S; Purushottamachar P; Ramamurthy VP; Njar VC
Oncotarget; 2015 Sep; 6(29):27440-60. PubMed ID: 26196320
[TBL] [Abstract][Full Text] [Related]
7. Galeterone activity in castration-resistant prostate cancer.
Yaqub F
Lancet Oncol; 2015 Jan; 16(1):e10. PubMed ID: 25638544
[No Abstract] [Full Text] [Related]
8. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.
Crona DJ; Milowsky MI; Whang YE
Clin Pharmacol Ther; 2015 Dec; 98(6):582-9. PubMed ID: 26331358
[TBL] [Abstract][Full Text] [Related]
9. Treatment With Galeterone in an Elderly Man With Castration-Resistant Prostate Cancer: A Case Report.
McKay RR; Mamlouk K; Montgomery B; Taplin ME
Clin Genitourin Cancer; 2015 Aug; 13(4):e325-e328. PubMed ID: 25600761
[No Abstract] [Full Text] [Related]
10. Phase I and II therapies targeting the androgen receptor for the treatment of castration resistant prostate cancer.
Dellis A; Papatsoris AG
Expert Opin Investig Drugs; 2016 Jun; 25(6):697-707. PubMed ID: 26954621
[TBL] [Abstract][Full Text] [Related]
11. Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.
Njar VC; Brodie AM
J Med Chem; 2015 Mar; 58(5):2077-87. PubMed ID: 25591066
[TBL] [Abstract][Full Text] [Related]
12. Salinization Dramatically Enhance the Anti-Prostate Cancer Efficacies of AR/AR-V7 and Mnk1/2 Molecular Glue Degraders, Galeterone and VNPP433-3β Which Outperform Docetaxel and Enzalutamide in CRPC CWR22Rv1 Xenograft Mouse Model.
Thankan RS; Thomas E; Purushottamachar P; Weber DJ; Njar VCO
Bioorg Chem; 2023 Oct; 139():106700. PubMed ID: 37392559
[TBL] [Abstract][Full Text] [Related]
13. Steroidogenic Metabolism of Galeterone Reveals a Diversity of Biochemical Activities.
Alyamani M; Li Z; Berk M; Li J; Tang J; Upadhyay S; Auchus RJ; Sharifi N
Cell Chem Biol; 2017 Jul; 24(7):825-832.e6. PubMed ID: 28648378
[TBL] [Abstract][Full Text] [Related]
14. Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.
Rathkopf DE; Larson SM; Anand A; Morris MJ; Slovin SF; Shaffer DR; Heller G; Carver B; Rosen N; Scher HI
Cancer; 2015 Nov; 121(21):3853-61. PubMed ID: 26178426
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer.
Dreicer R; MacLean D; Suri A; Stadler WM; Shevrin D; Hart L; MacVicar GR; Hamid O; Hainsworth J; Gross ME; Shi Y; Webb IJ; Agus DB
Clin Cancer Res; 2014 Mar; 20(5):1335-44. PubMed ID: 24418642
[TBL] [Abstract][Full Text] [Related]
16. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ;
Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
18. Transcriptome profiling reveals that VNPP433-3β, the lead next-generation galeterone analog inhibits prostate cancer stem cells by downregulating epithelial-mesenchymal transition and stem cell markers.
Thomas E; Thankan RS; Purushottamachar P; Huang W; Kane MA; Zhang Y; Ambulos N; Weber DJ; Njar VCO
Mol Carcinog; 2022 Jul; 61(7):643-654. PubMed ID: 35512605
[TBL] [Abstract][Full Text] [Related]
19. [Androgen receptor-mediated processes in castrate-resistant metastatic prostate cancer].
Küronya Z; Bíró K; Gyergyay F; Géczi L
Orv Hetil; 2017 Jan; 158(2):42-49. PubMed ID: 28088885
[TBL] [Abstract][Full Text] [Related]
20. Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer.
Agarwal N; Machiels JP; Suárez C; Lewis N; Higgins M; Wisinski K; Awada A; Maur M; Stein M; Hwang A; Mosher R; Wasserman E; Wu G; Zhang H; Zieba R; Elmeliegy M
Oncologist; 2016 May; 21(5):535-6. PubMed ID: 27091421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
